Allergan Patents Spared From PTAB Review In Settlement

Law360 (February 22, 2021, 6:55 PM EST) -- The Patent Trial and Appeal Board said it won't review six Allergan patents covering the company's injectable skin filler Juvederm, despite expressing skepticism toward them, after Allergan announced it has inked a licensing agreement with the low-cost rival challenging the patents.

The patent board announced Friday that it would be closing its review of the Allergan patents, which Prollenium US Inc. had challenged after AbbVie Inc.'s Allergan lodged two infringement suits against it in 2019 and 2020 in Delaware federal court. The companies on Friday also agreed to end those suits, and U.S. District Judge Colm Connolly signed off on the settlement on...

Stay ahead of the curve

In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.


  • Access to case data within articles (numbers, filings, courts, nature of suit, and more.)
  • Access to attached documents such as briefs, petitions, complaints, decisions, motions, etc.
  • Create custom alerts for specific article and case topics and so much more!

TRY LAW360 FREE FOR SEVEN DAYS

Hello! I'm Law360's automated support bot.

How can I help you today?

For example, you can type:
  • I forgot my password
  • I took a free trial but didn't get a verification email
  • How do I sign up for a newsletter?
Beta
Ask a question!